Description
A Two Part Phase IIa/b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension
Please contact: ClinicalResearch@sutterhealth.org about study AstraZeneca D4326C00003 ZEAL
Location: CPMC (San Francisco)